Australia's AdAlta soars to over a month high on cancer treatment partnership
02/01/2026 04:33
** Shares of AdAlta 1AD.AX rise as much as 33.4% to A$0.004, its biggest intraday pct gain in over a month ** Stock touches its highest level since November 24 ** Biotech firm says co and unit, AdCella have signed partnership agreement with Shanghai Cell Therapy Group to co-develop Chinese cell tech co's cancer treatment, BZDS1901, to markets outside China ** BZDS1901 targets specific proteins, treating aggressive and fatal cancers such as mesothelioma ** Stock fell 77.7% in 2025 (Reporting by Aamir Sheik Khalid in Bengaluru) ((Aamir.SheikKhalid@thomsonreuters.com))